Nippon Boehringer Ingelheim
CompanyJapan
Nippon Boehringer Ingelheim develops one asset. Mostly small molecule acting on ERBB2; based in Japan.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 1
- Signal
Pipeline
1Inhibits HER2 signaling to suppress growth of HER2-mutant cancer cells.
Stage not known, Small molecule, ERBB2
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Integrity notices1
- Similar companies3